Establishment of a new human iPSC cell line (UOMi007-A) from a patient with Hypophosphatasia

Stem Cell Res. 2022 Aug:63:102839. doi: 10.1016/j.scr.2022.102839. Epub 2022 Jun 8.

Abstract

Hypophosphatasia (HPP) is a rare, inherited, metabolic, genetic disorder, which arises due to loss of function mutation in the alkaline phosphatase (ALPL) gene. We have created a new induced pluripotent stem cell line (UOMi007-A) from peripheral blood mononuclear cells (PBMCs) of an 18 yr. old male patient having compound heterozygous mutations in the ALPL gene c.571G>A (p.Glu191Lys) and c.1001G>A (p.Gly334Asp) respectively. This line can be used for exploration into the molecular mechanisms of disease pathophysiology, screen new potential drugs and design cell therapy studies that can be personalized or used for future patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alkaline Phosphatase / genetics
  • Cell Line
  • Humans
  • Hypophosphatasia* / genetics
  • Induced Pluripotent Stem Cells*
  • Leukocytes, Mononuclear
  • Male
  • Mutation / genetics

Substances

  • Alkaline Phosphatase

Grants and funding